Exelan FDA Friday, August 26, 2016 0.00 Neutral

FDA Approves BUPROPION HYDROCHLORIDE (XL) — Exelan Pharmaceuticals Inc.

The FDA has granted final approval to Exelan Pharmaceuticals Inc. for its ANDA for bupropion hydrochloride, setting the stage for increased generic competition in this major antidepressant market.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day